354 related articles for article (PubMed ID: 9768527)
1. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome.
Delvaux M; Louvel D; Mamet JP; Campos-Oriola R; Frexinos J
Aliment Pharmacol Ther; 1998 Sep; 12(9):849-55. PubMed ID: 9768527
[TBL] [Abstract][Full Text] [Related]
2. Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome.
Thumshirn M; Coulie B; Camilleri M; Zinsmeister AR; Burton DD; Van Dyke C
Aliment Pharmacol Ther; 2000 Jul; 14(7):869-78. PubMed ID: 10886042
[TBL] [Abstract][Full Text] [Related]
3. Lipid-induced colonic hypersensitivity in irritable bowel syndrome: the role of 5-HT3 receptors.
Simrén M; Simms L; D'Souza D; Abrahamsson H; Björnsson ES
Aliment Pharmacol Ther; 2003 Jan; 17(2):279-87. PubMed ID: 12534414
[TBL] [Abstract][Full Text] [Related]
4. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers.
Houghton LA; Foster JM; Whorwell PJ
Aliment Pharmacol Ther; 2000 Jun; 14(6):775-82. PubMed ID: 10848662
[TBL] [Abstract][Full Text] [Related]
5. Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome.
Delvaux M; Beck A; Jacob J; Bouzamondo H; Weber FT; Frexinos J
Aliment Pharmacol Ther; 2004 Jul; 20(2):237-46. PubMed ID: 15233705
[TBL] [Abstract][Full Text] [Related]
6. Effect of alosetron on left colonic motility in non-constipated patients with irritable bowel syndrome and healthy volunteers.
Clemens CH; Samsom M; Van Berge Henegouwen GP; Fabri M; Smout AJ
Aliment Pharmacol Ther; 2002 May; 16(5):993-1002. PubMed ID: 11966509
[TBL] [Abstract][Full Text] [Related]
7. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome.
Bardhan KD; Bodemar G; Geldof H; Schütz E; Heath A; Mills JG; Jacques LA
Aliment Pharmacol Ther; 2000 Jan; 14(1):23-34. PubMed ID: 10632642
[TBL] [Abstract][Full Text] [Related]
8. Review article: clinical pharmacology of alosetron.
Gunput MD
Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():70-6. PubMed ID: 10429744
[TBL] [Abstract][Full Text] [Related]
9. The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients.
Mayer EA; Berman S; Derbyshire SW; Suyenobu B; Chang L; Fitzgerald L; Mandelkern M; Hamm L; Vogt B; Naliboff BD
Aliment Pharmacol Ther; 2002 Jul; 16(7):1357-66. PubMed ID: 12144587
[TBL] [Abstract][Full Text] [Related]
10. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist.
Camilleri M; Mayer EA; Drossman DA; Heath A; Dukes GE; McSorley D; Kong S; Mangel AW; Northcutt AR
Aliment Pharmacol Ther; 1999 Sep; 13(9):1149-59. PubMed ID: 10468696
[TBL] [Abstract][Full Text] [Related]
11. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients.
Jones RH; Holtmann G; Rodrigo L; Ehsanullah RS; Crompton PM; Jacques LA; Mills JG
Aliment Pharmacol Ther; 1999 Nov; 13(11):1419-27. PubMed ID: 10571597
[TBL] [Abstract][Full Text] [Related]
12. Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients.
Mangel AW; Northcutt AR
Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():77-82. PubMed ID: 10429745
[TBL] [Abstract][Full Text] [Related]
13. The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome.
Delvaux M; Louvel D; Lagier E; Scherrer B; Abitbol JL; Frexinos J
Gastroenterology; 1999 Jan; 116(1):38-45. PubMed ID: 9869600
[TBL] [Abstract][Full Text] [Related]
14. Oxytocin increases thresholds of colonic visceral perception in patients with irritable bowel syndrome.
Louvel D; Delvaux M; Felez A; Fioramonti J; Bueno L; Lazorthes Y; Frexinos J
Gut; 1996 Nov; 39(5):741-7. PubMed ID: 9014776
[TBL] [Abstract][Full Text] [Related]
15. Alosetron.
Balfour JA; Goa KL; Perry CM
Drugs; 2000 Mar; 59(3):511-8; discussion 519-20. PubMed ID: 10776833
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.
Camilleri M; Northcutt AR; Kong S; Dukes GE; McSorley D; Mangel AW
Lancet; 2000 Mar; 355(9209):1035-40. PubMed ID: 10744088
[TBL] [Abstract][Full Text] [Related]
17. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.
Camilleri M; Chey WY; Mayer EA; Northcutt AR; Heath A; Dukes GE; McSorley D; Mangel AM
Arch Intern Med; 2001 Jul; 161(14):1733-40. PubMed ID: 11485506
[TBL] [Abstract][Full Text] [Related]
18. Alosetron does not affect the visceral perception of gastric distension in healthy subjects.
Zerbib F; Bruley des Varannes S; Oriola RC; McDonald J; Isal JP; Galmiche JP
Aliment Pharmacol Ther; 1994 Aug; 8(4):403-7. PubMed ID: 7986965
[TBL] [Abstract][Full Text] [Related]
19. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome.
Watson ME; Lacey L; Kong S; Northcutt AR; McSorley D; Hahn B; Mangel AW
Am J Gastroenterol; 2001 Feb; 96(2):455-9. PubMed ID: 11232690
[TBL] [Abstract][Full Text] [Related]
20. Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients.
Wolfe SG; Chey WY; Washington MK; Harding J; Heath AT; McSorley DJ; Dukes GE; Hunt CM
Am J Gastroenterol; 2001 Mar; 96(3):803-11. PubMed ID: 11280555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
